amylyx pharmaceuticals inc - AMLX
AMLX
Close Chg Chg %
5.19 0.08 1.54%
Closed Market
5.27
+0.08 (1.54%)
Volume: 837.82K
Last Updated:
Nov 22, 2024, 4:00 PM EDT
Company Overview: amylyx pharmaceuticals inc - AMLX
AMLX Key Data
| Open $5.33 | Day Range 5.15 - 5.40 |
| 52 Week Range 1.58 - 19.95 | Market Cap $355.76M |
| Shares Outstanding 68.55M | Public Float 43.24M |
| Beta -0.70 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$3.82 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.69M |
AMLX Performance
| 1 Week | 10.71% | ||
| 1 Month | -0.75% | ||
| 3 Months | 136.32% | ||
| 1 Year | -59.98% | ||
| 5 Years | N/A |
AMLX Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
6
Full Ratings ➔
About amylyx pharmaceuticals inc - AMLX
Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.
AMLX At a Glance
Amylyx Pharmaceuticals, Inc.
43 Thorndike Street
Cambridge, Massachusetts 02141
| Phone | 1-617-682-0917 | Revenue | 380.79M | |
| Industry | Pharmaceuticals: Major | Net Income | 49.27M | |
| Sector | Health Technology | 2023 Sales Growth | 1,612.937% | |
| Fiscal Year-end | 12 / 2024 | Employees | 384 | |
| View SEC Filings |
AMLX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 20.909 |
| Price to Sales Ratio | 2.706 |
| Price to Book Ratio | 2.299 |
| Price to Cash Flow Ratio | 86.44 |
| Enterprise Value to EBITDA | 16.624 |
| Enterprise Value to Sales | 1.742 |
| Total Debt to Enterprise Value | 0.006 |
AMLX Efficiency
| Revenue/Employee | 991,630.208 |
| Income Per Employee | 128,309.896 |
| Receivables Turnover | 9.391 |
| Total Asset Turnover | 0.838 |
AMLX Liquidity
| Current Ratio | 5.664 |
| Quick Ratio | 5.197 |
| Cash Ratio | 4.526 |
AMLX Profitability
| Gross Margin | 93.033 |
| Operating Margin | 10.19 |
| Pretax Margin | 14.259 |
| Net Margin | 12.939 |
| Return on Assets | 10.842 |
| Return on Equity | 12.731 |
| Return on Total Capital | 11.258 |
| Return on Invested Capital | 12.629 |
AMLX Capital Structure
| Total Debt to Total Equity | 0.978 |
| Total Debt to Total Capital | 0.968 |
| Total Debt to Total Assets | 0.819 |
| Long-Term Debt to Equity | 0.457 |
| Long-Term Debt to Total Capital | 0.452 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Amylyx Pharmaceuticals Inc - AMLX
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 650.00K | 285.00K | 22.23M | 380.79M | |
Sales Growth
| -54.42% | -56.15% | +7,700.00% | +1,612.94% | |
Cost of Goods Sold (COGS) incl D&A
| - | 52.00K | 3.48M | 26.53M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 1.00K | 52.00K | 487.00K | 1.09M | |
Depreciation
| 1.00K | 52.00K | 487.00K | 1.09M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| - | - | +6,592.31% | +662.33% | - |
Gross Income
| - | 233.00K | 18.75M | 354.26M | |
Gross Income Growth
| - | - | +7,947.21% | +1,789.37% | - |
Gross Profit Margin
| - | +81.75% | +84.35% | +93.03% |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 39.65M | 82.92M | 220.09M | 315.45M | |
Research & Development
| 24.59M | 44.04M | 93.45M | 127.10M | |
Other SG&A
| 15.06M | 38.88M | 126.64M | 188.36M | |
SGA Growth
| +164.71% | +109.11% | +165.42% | +43.33% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | 1.27M | 5.23M | - |
EBIT after Unusual Expense
| (40.28M) | (87.92M) | (201.34M) | 38.80M | |
Non Operating Income/Expense
| 283.00K | (15.00K) | 3.74M | 15.49M | |
Non-Operating Interest Income
| 14.00K | 36.00K | 4.29M | 16.16M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | 2.29M | - |
Interest Expense Growth
| - | - | - | +79.31% | - |
Gross Interest Expense
| - | - | - | 2.29M | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (42.28M) | (87.93M) | (197.60M) | 54.30M | |
Pretax Income Growth
| -208.25% | -107.97% | -124.72% | +127.48% | |
Pretax Margin
| -6,504.62% | -30,852.98% | -888.89% | +14.26% | |
Income Tax
| - | - | 774.00K | 5.03M | - |
Income Tax - Current - Domestic
| - | - | - | 4.06M | - |
Income Tax - Current - Foreign
| - | - | 774.00K | 1.19M | - |
Income Tax - Deferred - Domestic
| - | - | - | (224.00K) | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (42.28M) | (87.93M) | (198.38M) | 49.27M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (42.28M) | (87.93M) | (198.38M) | 49.27M | |
Net Income Growth
| -208.25% | -107.97% | -125.60% | +124.84% | |
Net Margin Growth
| -6,504.62% | -30,852.98% | -892.38% | +12.94% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (42.28M) | (87.93M) | (198.38M) | 49.27M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (42.28M) | (87.93M) | (198.38M) | 49.27M | |
EPS (Basic)
| -0.7488 | -1.5196 | -2.9825 | 0.7328 | |
EPS (Basic) Growth
| -208.28% | -102.94% | -96.27% | +124.57% | |
Basic Shares Outstanding
| 56.47M | 57.86M | 66.51M | 67.23M | |
EPS (Diluted)
| -0.7488 | -1.5196 | -2.9825 | 0.704 | |
EPS (Diluted) Growth
| -208.28% | -102.94% | -96.27% | +123.60% | |
Diluted Shares Outstanding
| 56.47M | 57.86M | 66.51M | 69.99M | |
EBITDA
| (39.00M) | (82.64M) | (200.85M) | 39.89M | |
EBITDA Growth
| -187.77% | -111.87% | -143.06% | +119.86% | |
EBITDA Margin
| -6,000.62% | -28,995.09% | -903.53% | +10.48% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 6.167 | |
| Number of Ratings | 6 | Current Quarters Estimate | -0.564 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | -4.327 | |
| Last Quarter’s Earnings | -1.07 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 0.70 | Next Fiscal Year Estimate | -1.875 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 5 | 2 | 6 | 6 |
| Mean Estimate | -0.56 | -0.64 | -4.33 | -1.88 |
| High Estimates | -0.46 | -0.62 | -4.12 | -1.01 |
| Low Estimate | -0.66 | -0.65 | -4.51 | -2.82 |
| Coefficient of Variance | -13.99 | -3.34 | -3.92 | -36.53 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 2 | 2 | 1 |
| OVERWEIGHT | 1 | 0 | 0 |
| HOLD | 3 | 4 | 6 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Hold |
SEC Filings for Amylyx Pharmaceuticals Inc - AMLX
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Amylyx Pharmaceuticals Inc - AMLX
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| May 17, 2024 | Daphne E. Quimi Director | 2,750 | Open market or private purchase of non-derivative security Non-derivative transaction at $1.88 per share | 5,170.00 |
| May 17, 2024 | Daphne E. Quimi Director | 5,000 | Open market or private purchase of non-derivative security Non-derivative transaction at $1.89 per share | 9,450.00 |
| May 17, 2024 | Gina M. Mazzariello Chief Legal Officer | 151,477 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $1.88 per share | 284,776.76 |
| Apr 19, 2024 | James M. Frates Chief Financial Officer | 225,964 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 19, 2024 | James M. Frates Chief Financial Officer | 120,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 19, 2024 | Camille L. Bedrosian Chief Medical Officer | 155,243 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 19, 2024 | Camille L. Bedrosian Chief Medical Officer | 120,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 19, 2024 | Joshua B. Cohen Co-Chief Executive Officer; Director | 3,202,852 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 19, 2024 | Joshua B. Cohen Co-Chief Executive Officer; Director | 380,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 19, 2024 | Justin Klee Co-Chief Executive Officer; Director | 3,139,158 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 19, 2024 | Justin Klee Co-Chief Executive Officer; Director | 380,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 19, 2024 | Gina M. Mazzariello Chief Legal Officer | 110,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 29, 2024 | James M. Frates Chief Financial Officer | 60,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |